去铁酮治疗泛酸激酶相关神经变性的安全性和有效性:随机双盲对照试验及开放标签扩展研究
这项18个月随机双盲安慰剂对照试验纳入88例PKAN患者,评估去铁酮对脑铁沉积和疾病进展的影响;主要终点BAD量表组间差异未达统计学显著,扩展期显示从安慰剂换用去铁酮后进展似减缓,去铁酮耐受性良好但贫血更常见。
要点
- 去铁酮组贫血发生12例(21%),安慰剂组无贫血,但无因贫血停药。
核心结论
- 去铁酮耐受性良好并达到靶点结合(降低基底节铁),在18个月时似可一定程度上减缓疾病进展,但BAD量表评估未达统计学显著。
- 扩展研究额外18个月治疗结果佐证了上述发现,主观PGI-I量表在两个研究期间基本无变化,可能不适合评估PKAN疾病进展。
研究设计与样本
- 18个月随机双盲安慰剂对照试验(TIRCON2012V1)后接预定的18个月开放标签扩展研究,在德国、意大利、英国和美国四家医院进行。
- 筛查100例前瞻性患者后,88例随机分配(2:1)至去铁酮组(n=58)或安慰剂组(n=30),76例完成研究(去铁酮组49例,安慰剂组27例)。
- 纳入年龄≥4岁、基因确诊PKAN、BAD量表总分至少3分、无铁缺乏/中性粒细胞减少/肝肾功能异常证据的患者。
- 去铁酮口服溶液30 mg/kg/日分两次等量给药;共同主要终点为基线至第18个月BAD量表总分变化和第18个月PGI-I评分。
主要发现
- 去铁酮组贫血12例(21%),安慰剂组无贫血;无患者因贫血停药,3例因中度中性粒细胞减少停药;扩展研究每组各1例死亡,均继发于误吸,均认为与去铁酮无关。
关键数值与推荐
- 共同主要终点:基线至第18个月BAD量表总分变化和第18个月PGI-I评分。
临床怎么用
- 去铁酮30 mg/kg/日分两次给药在PKAN患者中耐受性良好,但需监测贫血和中性粒细胞减少。
- BAD量表可用于评估PKAN疾病进展,PGI-I可能不适合作为PKAN进展的评估工具。
- 去铁酮对PKAN疾病进展的减缓作用未达统计学显著,临床决策需结合个体情况。
局限性
- PGI-I量表在两个研究期间基本无变化,可能不是评估PKAN疾病进展的 adequate 工具。
- 扩展研究为单臂开放标签设计,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pantothenate kinase-associated neurodegeneration (PKAN) is a rare genetic disorder characterised by progressive generalised dystonia and brain iron accumulation. We assessed whether the iron chelator deferiprone can reduce brain iron and slow disease progression. METHODS: We did an 18-month, randomised, double-blind, placebo-controlled trial (TIRCON2012V1), followed by a pre-planned 18-month, open-label extension study, in patients with PKAN in four hospitals in Germany, Italy, England, and the USA. Patients aged 4 years or older with a genetically confirmed diagnosis of PKAN, a total score of at least 3 points on the Barry-Albright Dystonia (BAD) scale, and no evidence of iron deficiency, neutropenia, or abnormal hepatic or renal function, were randomly allocated (2:1) to receive an oral solution of either deferiprone (30 mg/kg per day divided into two equal doses) or placebo for 18 months. Randomisation was done with a centralised computer random number generator and with stratification based on age group at onset of symptoms. Patients were allocated to groups by a randomisation team not masked for study intervention that was independent of the study. Patients, caregivers, and investigators were masked to treatment allocation. Co-primary endpoints were the change from baseline to month 18 in the total score on the BAD scale (which measures severity of dystonia in eight body regions) and the score at month 18 on the Patient Global Impression of Improvement (PGI-I) scale, which is a patient-reported interpretation of symptom improvement. Efficacy analyses were done on all patients who received at least one dose of the study drug and who provided a baseline and at least one post-baseline efficacy assessment. Safety analyses were done for all patients who received at least one dose of the study drug. Patients who completed the randomised trial were eligible to enrol in a single-arm, open-label extension study of another 18 months, in which all participants received deferiprone with the same regimen as the main study. The trial was registered on ClinicalTrials.gov, number NCT01741532, and EudraCT, number 2012-000845-11. FINDINGS: Following a screening of 100 prospective patients, 88 were randomly assigned to the deferiprone group (n=58) or placebo group (n=30) between Dec 13, 2012, and April 21, 2015. Of these, 76 patients completed the study (49 in the deferiprone group and 27 in the placebo group). After 18 months, the BAD score worsened by a mean of 2·48 points (SE 0·63) in patients in the deferiprone group versus 3·99 points (0·82) for patients in the control group (difference -1·51 points, 95% CI -3·19 to 0·16, p=0·076). No subjective change was detected as assessed by the PGI-I scale: mean scores at month 18 were 4·6 points (SE 0·3) for patients in the deferiprone group versus 4·7 points (0·4) for those in the placebo group (p=0·728). In the extension study, patients continuing deferiprone retained a similar rate of disease progression as assessed by the BAD scale (1·9 points [0·5] in the first 18 months vs 1·4 points [0·4] in the second 18 months, p=0·268), whereas progression in patients switching from placebo to deferiprone seemed to slow (4·4 points [1·1] vs 1·4 points [0·9], p=0·021). Patients did not detect a change in their condition after the additional 18 months of treatment as assessed by the PGI-I scale, with mean scores of 4·1 points [0·2] in the deferiprone-deferiprone group and of 4·7 points [0·3] in the placebo-deferiprone group. Deferiprone was well tolerated and adverse events were similar between the treatment groups, except for anaemia, which was seen in 12 (21%) of 58 patients in the deferiprone group, but was not seen in any patients in the placebo group. No patient discontinued therapy because of anaemia, and three discontinued because of moderate neutropenia. There was one death in each group of the extension study and both were secondary to aspiration. Neither of these events was considered related to deferiprone use. INTERPRETATION: Deferiprone was well tolerated, achieved target engagement (lowering of iron in the basal ganglia), and seemed to somewhat slow disease progression at 18 months, although not significantly, as assessed by the BAD scale. These findings were corroborated by the results of an additional 18 months of treatment in the extension study. The subjective PGI-I scale was largely unchanged during both study periods, indicating that might not be an adequate tool for assessment of disease progression in patients with PKAN. Our trial provides the first indication of a decrease in disease progression in patients with neurodegeneration with brain iron accumulation. The extensive information collected and long follow-up of patients in the trial will improve the definition of appropriate endpoints, increase the understanding of the natural history, and thus help to shape the design of future trials in this ultra-orphan disease. FUNDING: European Commission, US Food and Drug Administration, and ApoPharma Inc.
引用
- Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019. PMID: 31202468. doi:10.1016/S1474-4422(19)30142-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。